Bookmark and Share
BioAssay: AID 1971

Broad Institute MLPCN Hypoxia Inducible Factor Activation Project

Dr. Shawn R. Gilbert,University of Alabama, 1600 7th Ave S, Children's Hospital Pediatrics Orthopaedic, Suite ACC316, Birmingham, AL 35233Shawn.Gilbert2@ORTHO.UAB.EDU ..more
_
   
 Related BioAssays
 Related BioAssays
AID: 1971
Data Source: Broad Institute (2030_Activators)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-10-09
Modify Date: 2011-04-05
Related Experiments
Show more
AIDNameTypeComment
1910Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor PathwayScreeningdepositor-specified cross reference: 300409 hts compounds at singlepoint in HRE luciferase assay measuring activityactivity in these cell
2089Luminescence Cell-Based Confirmation at Dose to Identify Transcriptional Activators of Hypoxia-Inducible Factor PathwayConfirmatorydepositor-specified cross reference: 1169 cherrypick compounds at dose in 01 HRE luciferase assay measuring activity
2486Luminescent Cell-Based Dose Titration Retest Counterscreen to Identify Proteasome InhibitorsConfirmatorydepositor-specified cross reference: 1155 cherrypick compounds at dose in Counter Screen Proteasome Inhibitors measuring activity set 1
434951Fluorescent Cell-Based Secondary Screen to Identify Activators of the Hypoxia Factor PathwayConfirmatorydepositor-specified cross reference: 1169 cherrypick compounds at dose in High Content Imaging measuring activity set 1
488804Proteasome Measured in Cell-Based System Using Plate Reader - 2030-02_Activator_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 59 drypowder compounds at dose in Counter Screen Proteasome Inhibitors measuring activity set 2
488805Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 59 drypowder compounds at dose in HRE luciferase assay measuring activity set 2
488820Hypoxia Inducible pathway Measured in Cell-Based System Using Imaging - 2030-03_Activator_Dose_DryPowder_ActivityConfirmatorydepositor-specified cross reference: 59 drypowder compounds at dose in High Content Imaging measuring activity set 1
488843HIF pathway Measured in Cell-Based System Using RT-PCR - 2030-04_Activator_Dose_DryPowder_ActivityConfirmatorydepositor-specified cross reference: 59 drypowder compounds at dose in VEGF and HIF RT-PCR measuring activity set 1
493180Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set3Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE luciferase assay measuring activity set 3
493193Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set4Confirmatorydepositor-specified cross reference: 31 drypowder compounds at dose in HRE luciferase assay measuring activity set 4
493195Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set6Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE luciferase assay measuring activity set 6
493213Counterscreen Measured in Cell-Based System Using Plate Reader - 2030-02_Activator_Dose_DryPowder_Activity_Set3Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in Counter Screen Proteasome Inhibitors measuring activity set 3
493225Hypoxia inducible pathway Measured in Cell-Based System Using Imaging - 2030-03_Activator_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in High Content Imaging measuring activity set 2
493227Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set8Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE luciferase assay measuring activity set 8
493228Hypoxia inducible factor pathway Iron Measured in Cell-Based System Using Plate Reader - 2030-06_Activator_Dose_DryPowder_ActivityConfirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in 06 HRE Luciferase_Iron measuring activity
493230HIF pathway Measured in Cell-Based System Using RT-PCR - 2030-04_Activator_Dose_DryPowder_Activity_Set3Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in VEGF and HIF RT-PCR measuring activity set 3
493234Hypoxia inducible factor pathway Zinc Measured in Cell-Based System Using Plate Reader - 2030-05_Activator_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE luciferase_zinc measuring activity set 2
493235Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set7Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE luciferase assay measuring activity set 7
493236Counterscreen Measured in Cell-Based System Using Plate Reader - 2030-02_Activator_Dose_DryPowder_Activity_Set4Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in Counter Screen Proteasome Inhibitors measuring activity set 4
493237Hypoxia inducible factor pathway Iron Measured in Cell-Based System Using Plate Reader - 2030-06_Activator_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE Luciferase_Iron measuring activity set 2
493238HIF pathway Measured in Cell-Based System Using RT-PCR - 2030-04_Activator_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in VEGF and HIF RT-PCR measuring activity set 2
493239Hypoxia inducible pathway Measured in Cell-Based System Using Imaging - 2030-03_Activator_Dose_DryPowder_Activity_Set3Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in High Content Imaging measuring activity set 3
493249Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Toxicity_Set7Confirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in HRE luciferase assay measuring toxicity set 7##
504323Hypoxia inducible factor pathway Zinc Measured in Cell-Based System Using Plate Reader - 2030-05_Activator_Dose_DryPowder_ToxicityConfirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in 05 HRE luciferase_zinc measuring toxicity
504324Hypoxia inducible factor pathway Zinc Measured in Cell-Based System Using Plate Reader - 2030-05_Activator_Dose_DryPowder_ActivityConfirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in 05 HRE luciferase_zinc measuring activity
504331Hypoxia inducible factor pathway Iron Measured in Cell-Based System Using Plate Reader - 2030-06_Activator_Dose_DryPowder_ToxicityConfirmatorydepositor-specified cross reference: 90 drypowder compounds at dose in 06 HRE Luciferase_Iron measuring toxicity
504588Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set10Confirmatorydepositor-specified cross reference: 6 drypowder compounds at dose in HRE luciferase assay measuring activity set 10
504597Hypoxia inducible factor pathway Measured in Cell-Based System Using Plate Reader - 2030-01_Activator_Dose_DryPowder_Activity_Set9Confirmatorydepositor-specified cross reference: 6 drypowder compounds at dose in HRE luciferase assay measuring activity set 9
Description:
Primary Collaborators:
Dr. Shawn R. Gilbert,University of Alabama, 1600 7th Ave S, Children's Hospital Pediatrics Orthopaedic, Suite ACC316, Birmingham, AL 35233Shawn.Gilbert2@ORTHO.UAB.EDU

Biological Relevance:
Enhancing blood supply is a common goal in the setting of ischemia due to injury or disease. The central pathway for cellular response to hypoxia is the hypoxia inducible factor (HIF)pathway. HIFs are transcription factors which activate genes encoding proteins that mediate adaptive responses to reduced oxygen availability (e.g. angiogenesis). The HIF complex consists of a heterodimer comprised of one of three alpha subunits (HIF-1alpha, HIF-2alpha, or HIF-3alpha)bound to the aryl hydrocarbon receptor nuclear translocator (ARNT), which is also known as HIF-1beta. Hypoxia induces changes in the accumulation and activity of the HIF-1alpha subunit. In most cells, the primary level of regulation is inhibition of the HIF-1alpha subunit degradation during hypoxia. Generally, the level of HIF-1alpha protein is low due to the on-going ubiquitination and proteosomal degradation. The molecular mechanism of degradation of HIF-1alpha subunits involves enzymatic prolyl hydroxylation on an oxygen degradation domain (ODD) which targets HIF-1alpha for ligation-mediated proteosomal degradation. The conserved proline residue is hydroxylated under normoxic conditions by one of a group of three prolyl hydroxylases (PHDs 1-3) . The reaction requires the presence of iron, oxygen and 2-oxoglutarate. Following prolyl hydroxylation, the HIF molecule is recognized by the Von Hippel Lindau (VHL) ubiquitinproteinligase. During hypoxia, prolyl hydroxylation is blocked, leading to HIF-1alphastabilization. A negative feedback loop is established whereby hypoxia and HIF-1alpha both upregulate PHD2 expression. This process results in accumulation of functional HIF-1alpha subunits, which dimerize with ARNT and translocate to the nucleus. In the nucleus, the HIF-1alpha/ARNT complex can couple with the coactivator p300, bind to hypoxia response elements (HREs) in the proximal promoter regions and transactivate HIF-sensitive genes which include metabolic pathways such as glut1 and angiogenic factors, such as VEGF. A further regulatory step exists, however. Hydroxylation of an asparagine residue by the factor inhibiting HIF (FIH) found within the nucleus can block the HIF/p300 association. The elucidation of these pathways has enabled strategies for experimental activation or inhibition of HIF.

Project Goal:
Many disease processes and injuries have in common poor blood supply and/or lack of oxygen. The current proposal seeks to find agents that can activate the hypoxia inducible factor pathway which is responsible for initiating a response to low oxygen that includes metabolic adaptation and development of increased blood supply. These activators of the HIF pathway may be useful in a broad range of diseases such as heart disease and limb ischemia and in approaches to tissue regeneration. The current proposal seeks to find probes that can activate the hypoxia inducible factor pathway which is responsible for initiating a response to low oxygen that includes metabolic adaptation and development of increased blood supply.
1)Probe attributes:
a.Identify probes that activate HIF through mechanisms other then prolyl hydroxylation.
b.Identify probes that more specifically target the HIF prolyl hydoroxylases (PHDs).
c.Identify probes with higher potency than Desferrioxamine (EC50 of DFO is 17.8 muM).

Keywords: Hypoxia, tissue regeneration, ischemia
Additional Information
Grant Number: 1 R03 MH082355-01A2

PageFrom: